Pig kidney transplant trial for kidney failure patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a genetically modified pig kidney (Thymokidney) for people with end-stage kidney disease who are on dialysis. It aims to see if this new type of transplant is safe and effective for those who cannot get a human kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be on dialysis for at least 6 months and have a working access (fistula, graft, or catheter).
- You must be between 50 and 70 years old, or 40 to 49 with very high antibody levels (cPRA ≥99.9%).
- You must live within 3 hours of the transplant center.
- You need to be up to date on certain vaccines and have had past infections with CMV and Epstein-Barr virus (common viruses).
- You cannot have other serious medical issues like advanced heart or lung disease, active cancer, or uncontrolled diabetes.
- You must be willing and able to follow all study requirements and not have a history of medical noncompliance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special pig kidney (10 GE Xenokidney) as a transplant option for people with kidney failure who cannot get a human kidney. It aims to offer a life-saving alternative.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This trial tests a new type of kidney transplant using a genetically modified pig kidney (called a xenograft). It is for people with end-stage kidney disease who have been on dialysis and are not likely to get a human donor kidney soon. The goal is to see if this pig kidney can work safely as an alternative.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This study is testing a new way to help the body accept a kidney transplant without needing lifelong anti-rejection drugs. It involves transplanting a small piece of the donor's thymus (a gland that helps the immune system) along with the kidney, to train the body to see the new kidney as part of itself.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.